格隆汇12月29日丨蓝丰生化(002513.SZ)公布，基于宁夏蓝丰的实际经营情况，无法全部以现金方式清 偿公司债务。为加快债权清收，实现资金回笼，改善资产结构，优化公司财务状况，保障公司及全体股 东利益，公司作为债权人拟通过取得宁夏蓝丰所持有的地下车位使用权及车库机械设备所有权（简 称"标的资产"）用于抵偿宁夏蓝丰所欠公司款项，以上交易构成债务重组。 ...

格隆汇12月29日丨蓝丰生化(002513.SZ)公布，基于宁夏蓝丰的实际经营情况，无法全部以现金方式清 偿公司债务。为加快债权清收，实现资金回笼，改善资产结构，优化公司财务状况，保障公司及全体股 东利益，公司作为债权人拟通过取得宁夏蓝丰所持有的地下车位使用权及车库机械设备所有权（简 称"标的资产"）用于抵偿宁夏蓝丰所欠公司款项，以上交易构成债务重组。 ...

本资产评估报告依据中国资产评估准则编制 江苏蓝丰生物化工股份有限公司拟接受资产抵偿债务 所涉及的宁夏蓝丰精细化工有限公司持有的 车位使用权及车库机械设备市场价值 产评估报告 深国誉评报字 ZB[2025]第 352 号 评估基准日:2025年 10 月 31 日 资产评估报告日:2025年12月5日 GUOYU EVALUATION 深圳市国誉资产评估房地) 曲信 分 顾问有限公司 中国深圳市南山区粤海 道深圳湾科技生态园 12 栋裙楼 711 江苏蓝丰生物化工股份有限公司拟接受资产抵偿债务 所涉及的车位使用权及车库机械设备市场价值 · 资产评估报告 | | | | 目 录 . | | --- | | 声 明 | | 资产评估报告摘要 | | 资产评估报告正文 | | í 委托人、产权持有人和资产评估委托合同约定的其他资产评估报告使用人 .. 6 | | ニ、 评估目的 . | | =、 评估对象和评估范围 . | | 价值类型 . 四、 | | 五、 评估基准日 | | 六、 评估依据 | | 七、 评估方法 . | | 八、 评估程序实施过程和情况 | | 九、 评估结论 . | | 十、 特别事项说明 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-081 江苏蓝丰生物化工股份有限公司 第七届董事会第三十一次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 表决结果：8 票同意，0 票反对，0 票弃权。 具体详见 2025 年 12 月 30 日刊登在公司指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）及《上海证券报》《证券时报》《中国证券报》上的相 关公告。 （二）审议通过《关于控股股东豁免借款利息暨关联交易的议案》 为支持公司持续稳健发展，缓解公司债务压力，公司控股股东、实际控制人 郑旭先生豁免其对公司及公司控股子公司江苏蓝丰生物化工有限公司借款的应 1 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届董事会第三十 一次会议于 2025 年 12 月 29 日以通讯方式召开。本次会议已于 2025 年 12 月 26 日以微信、电子邮件的方式通知全体董事。本次会议由公司董事长郑旭先生主持， 会议应出席董事 8 人，实际出席董事 8 人，公司高级管理人员列席会议。本次会 议的召集、召 ...

Group 1 - The core viewpoint of the news is that Jiangsu Lanfeng Bio-chemical Co., Ltd. has shown significant stock performance and financial metrics, indicating potential investment interest [1][2]. - As of December 26, Lanfeng's stock price increased by 2.04% to 6.99 CNY per share, with a total market capitalization of 2.625 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 56.03%, although it has seen a decline of 9.34% over the past 20 days and 10.50% over the past 60 days [1]. Group 2 - Lanfeng's main business includes the production and sales of pesticide raw materials and formulations, with revenue contributions from battery cells (43.84%), components (31.70%), and pesticide products (17.20%) [2]. - As of September 30, the company reported a total revenue of 1.83 billion CNY for the first nine months of 2025, reflecting a year-on-year growth of 28.26%, while the net profit attributable to shareholders was a loss of 77.18 million CNY, an increase in loss of 58.29% [2]. - The company has a total of 41,700 shareholders, which is an increase of 48.71% compared to the previous period, with an average of 6,360 circulating shares per shareholder, a decrease of 32.41% [2].

Group 1 - The core viewpoint of the news is that Jiangsu Lanfeng Bio-chemical Co., Ltd. has shown significant stock performance and financial growth in 2023, with a notable increase in share price and trading activity [1][2]. - As of December 23, Lanfeng Bio-chemical's stock price increased by 54.02% year-to-date, with a recent trading volume of 72.55 million yuan and a market capitalization of 2.592 billion yuan [1]. - The company has been active in the stock market, appearing on the "Dragon and Tiger List" 18 times this year, with a total net buy of 61.218 million yuan on the most recent occasion [1]. Group 2 - Lanfeng Bio-chemical, established in 1990 and listed in 2010, specializes in the production and sales of pesticides and fine chemical intermediates, with a revenue composition of 43.84% from battery cells, 31.70% from modules, and 17.20% from pesticide raw materials [2]. - As of September 30, the company reported a revenue of 1.83 billion yuan for the first nine months of 2025, reflecting a year-on-year growth of 28.26%, while the net profit attributable to shareholders was a loss of 77.1821 million yuan, an increase of 58.29% compared to the previous year [2]. - The company has not distributed dividends in the last three years, with a total payout of 88.0179 million yuan since its A-share listing [3].

截至本公告披露日，公司已收到海南闻勤支付的全部业绩补偿款。至此，海南闻勤拍卖所得限制性股票 23,793,411股对应的业绩补偿义务已全部履行完毕。 格隆汇12月22日丨蓝丰生化(002513.SZ)公布，近日，为解决限售股解除限售事宜，经友好协商，公司 与海南闻勤就业绩补偿支付及解除股票限售达成协议，本协议项下海南闻勤应支付蓝丰生化的业绩补偿 款总额为人民币柒仟壹佰肆拾壹万肆仟贰佰壹拾贰元伍角叁分（小写：¥71,414,212.53元）,含本金及违 约金。 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-079 江苏蓝丰生物化工股份有限公司 关于收到业绩补偿款的公告 1 息披露网站巨潮资讯网（www.cninfo.com.cn）及《上海证券报》《证券时报》 《中国证券报》上的《2021 年第三季度报告》第三部分"其他重要事项"中相 关内容。2022 年 2 月 20 日，公司向徐州中院提出强制执行申请。执行过程中， 徐州中院依职权对王宇的财产进行了调查，未发现有其他可供执行的财产，2022 年 8 月 10 日，徐州中院作出（2022）苏 03 执 149 号之一《执行裁定书》，裁定 "终结本院（2021）苏民初 216 号民事判决书的本次执行程序"。截止到本公告 日，公司尚未收到王宇支付的业绩补偿款。 二、王宇所持公司股份被司法拍卖的情况 2023 年 9 月，王宇所持有的无限售流通股 9,816,589 股和有限售股 23,793,411 股，合计 33,610,000 股（以下简称"标的股份"）因涉及其他诉讼 被陕西省西安市中级人民法院在淘宝网司法网络拍卖平台上公开拍卖，根据淘宝 网司法拍卖网络平台公示的《网络竞价成功确认书》，上述股份被海 ...

Group 1 - The core point of the article is that Lanfeng Biochemical announced the approval of a proposal regarding the capital increase and expansion of its controlling subsidiary, while the company will waive its preemptive subscription rights [2] Group 2 - The announcement was made during the 30th meeting of the 7th Board of Directors [2]

Core Viewpoint - The company announced a capital increase for its subsidiary, Jiangsu Lanfeng Biochemical Co., Ltd., to support its operational development, with a total investment of RMB 30 million [1] Group 1: Capital Increase Details - The capital increase will be conducted by one of the original shareholders, Yuanjiang Bide Chemical Co., Ltd., through a cash injection of RMB 30 million, of which RMB 3 million will be added to the registered capital and RMB 27 million to the capital reserve [1] - Other original shareholders, Anhui Xuhe Capital Holdings Co., Ltd. and Jiangsu Suhua Group Co., Ltd., will waive their preferential subscription rights for this capital increase [1] Group 2: Impact on Shareholding Structure - Following the completion of the capital increase, the registered capital of Lanfeng Biochemical will rise from RMB 130 million to RMB 133 million [1] - The company's ownership stake in Lanfeng Biochemical will decrease from 76.92% to 75.19%, but Lanfeng Biochemical will remain a subsidiary controlled by the company, and there will be no change in the scope of the company's consolidated financial statements [1]